Impelpharma

Impel Pharmaceuticals is a commercial-stage pharmaceutical company developing first-in-class intranasal drug treatments for central nervous system (CNS) disorders with high unmet medical needs. Its proprietary Precision Olfactory Delivery (POD) technology targets the vascular-rich upper nasal cavity to achieve more rapid and consistent bioavailability than conventional delivery. Its lead product, Trudhesa (dihydroergotamine mesylate) nasal spray, is approved for the acute treatment of migraine with or without aura in adults. Impel was backed by Norwest Venture Partners (co-led its 2018 Series D) and later filed for bankruptcy in December 2023. This is a patient- and science-facing pharma company with no public developer API, SDK, or documentation surface.

Impelpharma is profiled on the APIs.io network. Tagged areas include Company, Pharmaceutical, Drug Delivery, Healthcare, and Biotechnology.

Impelpharma’s developer surface includes engineering blog, support, and 4 more developer resources.

🌐 Visit website 📡 Source on GitHub

15.0/100 emerging ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyPharmaceuticalDrug DeliveryHealthcareBiotechnologyMigraineCNSNasal DeliveryLife Sciences

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 15.0/100 · emerging

Contract Quality 0.0 / 25

Developer Ergonomics 1.3 / 20

Commercial Clarity 4.2 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/impelpharma: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Company 2

The organization behind the API

Website

Website

Blog

Blog

Source (apis.yml)

aid: impelpharma
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/impelpharma.png
name: Impelpharma
description: Impel Pharmaceuticals is a commercial-stage pharmaceutical company developing first-in-class intranasal drug
  treatments for central nervous system (CNS) disorders with high unmet medical needs. Its proprietary Precision Olfactory
  Delivery (POD) technology targets the vascular-rich upper nasal cavity to achieve more rapid and consistent bioavailability
  than conventional delivery. Its lead product, Trudhesa (dihydroergotamine mesylate) nasal spray, is approved for the acute
  treatment of migraine with or without aura in adults. Impel was backed by Norwest Venture Partners (co-led its 2018 Series
  D) and later filed for bankruptcy in December 2023. This is a patient- and science-facing pharma company with no public
  developer API, SDK, or documentation surface.
url: https://raw.githubusercontent.com/api-evangelist/impelpharma/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- norwest-venture-partners
x-tier: stub
x-tier-reason: portfolio-lead
x-sector: pharmaceutical
x-note: No developer/API surface as of 2026-07; company filed for bankruptcy December 2023.
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Pharmaceutical
- Drug Delivery
- Healthcare
- Biotechnology
- Migraine
- CNS
- Nasal Delivery
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://impelpharma.com
- type: Blog
  url: https://impelpharma.com/category/publications/
- type: Support
  url: https://impelpharma.com/contact/
- type: PrivacyPolicy
  url: https://impelpharma.com/privacy-policy/
- type: TermsOfService
  url: https://impelpharma.com/terms-of-service/
- type: DomainSecurity
  url: security/impelpharma-domain-security.yml
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence